IP Library › Granted Patent US 12,486,274
Granted Patent B2
US 12,486,274 · App. 17/792,304 · Granted Dec 2, 2025

Substituted pyrazolo-pyrimidines and uses thereof

Inventors: Mark D. Rosen (South San Francisco, CA); Robert A. Galemmo, Jr. (San Francisco, CA); Weiling Liang (South San Francisco, CA); Brian Kopec (South San Francisco, CA); Irene Y. Choi-Muckerheide (Pacifica, CA); Jane Rhodes (South San Francisco, CA)
Assignee: Verge Analytics, Inc.
C07D487/04A61P25/28C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,486,274
App. No.
17/792,304
Granted
Dec 2, 2025
Kind
B2
Abstract

The present disclosure provides compounds that are inhibitors of PIKfyve kinases useful for the treatment of neurological diseases treatable by inhibition of PIKfyve. Also provided are pharmaceutical compositions containing such compounds, and methods of treatment using such compounds.

Claims (183)

1 . A compound of Formula (I):

wherein:

X is N or CH, Y is N or CR a provided that when X is N, then Y is CR a , when Y is N, then X is CH;

one of R a and R l is H, and the other is phenyl or heteroaryl, each optionally substituted with one, two, or three R d substituents;

wherein each R d substituent is independently C 1-4 alkyl, C 1-4 alkenyl, C 1-4 alkynyl, —O—C 1-4 alkyl, halo, cyano, nitro, azido, halo-C 1-4 alkyl, —O—C 1-4 -haloalkyl, —NR g R h , —NR g C(═O)R h , —NR g C(═O)NR g R h , —NR g C(═O)OR h , ═NOR g , —NR g S(═O) 1-2 R h , —NR g S(═O) 1-2 NR g R h , ═NSO 2 R g , —C(═O)R g , —C(═O)OR g , —OC(═O)OR g , —OC(═O)R g , —C(═O)NR g R h , —OC(═O)NR g R h , —OR g , —SR g , —S(═O)R g , —S(═O) 2 R g , —OS(═O) 1-2 R g , —S(═O) 1-2 OR g , —S(═O) 1-2 NR g R h , phenyl, —C 1-4 alkyl-phenyl, monocyclic cycloalkyl, —C 1-4 alkyl-cycloalkyl, monocyclic heterocycloalkyl, or monocyclic heteroaryl;

wherein each phenyl, monocyclic cycloalkyl, monocyclic heterocycloalkyl, or monocyclic heteroaryl of R d is optionally substituted with one, two, or three substituents R e ;

wherein each R e substituent is independently C 1-4 alkyl, C 1-4 alkenyl, C 1-4 alkynyl, halo, cyano, nitro, azido, —OH, halo-C 1-4 alkyl, —O—C 1-4 alkyl, or —O—C 1-4 -haloalkyl;

R g and R h are each independently H or C 1-4 alkyl;

or R g and R h taken together with the atom to which they are attached form a monocyclic cycloalkyl or heterocycloalkyl, optionally substituted with C 1-4 alkyl;

wherein each of R 2 and R 3 is H or is a C 1-4 alkyl, cycloalkyl, C 1-4 alkylcycloalkyl, heterocyclyl, heterocycloalkyl, or R 2 and R 3 taken together with the nitrogen to which they are attached form a heterocyclyl, optionally substituted with one, two, or three R j substituents;

wherein each R j substituent is independently C 1-4 alkyl, oxo, —OH, —NR k R l , halo, halo-C 1-4 alkyl,

—O—C 1-4 alkyl, or —O—C 1-4 -haloalkyl;

where R k and R l are each independently H or C 1-4 alkyl;

R 4 is —C(O)NR x R y , or is a phenyl or heteroaryl, each optionally substituted with one, two, or three R z substituents;

wherein R x is H or C 1-4 alkyl and R y is H, C 1-4 alkyl, —O—C 1-4 alkyl, —SO 2 —C 1-4 alkyl, C 1-4 alkyl-SO 2 —R r , monocyclic cycloalkyl, —C 1-4 alkyl(monocyclic cycloalkyl), monocyclic heterocyclyl, —O-monocyclic heterocyclyl, or monocyclic heterocycloalkyl, each optionally substituted with one, two, or three R g substituents;

or R x and R y taken together with the nitrogen to which they are attached form a heterocyclyl or a monocyclic heterocycloalkyl, optionally substituted with C 1-4 alkyl;

wherein each R r is C 1-4 alkyl or —NR p R q ; and

each R z substituent is independently C 1-4 alkyl, halo, —OH, or —OC 1-4 alkyl, C 1-4 alkylNR m R n , C(O)NHC 1-4 alkyl-NR m R n , or —NR m R n ;

wherein R m and R n are each independently H, C 1-4 alkyl, or C 1-4 alkylNR p R q , or R m and R n taken together with the nitrogen to which they are attached form a heterocyclyl, or a monocyclic heterocycloalkyl, optionally substituted with one or two R g substituents;

wherein each R o substituent is independently C 1-4 alkyl, —OH, —OC 1-4 alkyl, halo, cyano, or —NR p R q ;

 wherein R p and R q are each independently H or C 1-4 alkyl, or R p and R q taken together with the nitrogen to which they are attached form a heterocyclyl; and

R 5 is H, C 1-4 alkyl, halo, —OH, or —OC 1-4 alkyl;

or a pharmaceutically acceptable salt thereof.

2 . The compound of claim 1 , wherein X is N and Y is CR a .

3 . The compound of claim 1 , wherein R a is H.

4 . The compound of claim 1 , wherein R a or R l is optionally substituted phenyl.

5 . The compound of claim 1 , wherein R a or R l is unsubstituted phenyl or m-tolyl.

6 . The compound of claim 1 , wherein R 2 and R 3 taken together with the nitrogen to which they are attached form pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, thiomorpholine-1,1-dioxide, or 2-oxa-6-azaspiro[3.3]heptane, each optionally substituted with one, two, or three R j substituents.

7 . The compound of claim 1 , wherein R 2 and R 3 taken together with the nitrogen to which they are attached form morpholine, optionally substituted with one or two R j substituents.

8 . The compound of claim 1 , wherein R 4 is optionally substituted heteroaryl.

9 . The compound of claim 1 , wherein R 4 is optionally substituted pyrazole, thiazole, oxazole, pyridine or pyrimidine.

10 . The compound of claim 1 , wherein R 4 is pyrazole optionally substituted with one or two R z substituents.

11 . The compound of claim 1 , wherein each R z is independently methyl, —OH, halo, or —OCH 3 .

12 . The compound of claim 1 , wherein R 5 is H, methyl, ethyl, chloro, bromo, fluoro, —OH, or —OCH 3 .

13 . The compound of claim 1 , wherein R 5 is H.

14 . A compound of Formula (II):

wherein

R 1a is phenyl or pyridyl, each optionally substituted with one or two substituents selected from C 1-4 alkyl, CO 2 R p , —C(O)NR p R q , fluoro, chloro, bromo, NH 2 , and —OCH 3 ; and

R 4a is —C(O)NR x R y , or is a phenyl, pyrazole, or pyridyl, each optionally substituted with one or two substituents selected from C 1-4 alkyl, —CF 3 , fluoro, chloro, —OCH 3 , and —OCF 3 ;

wherein R x is H or C 1-4 alkyl and R y is H, C 1-4 alkyl, —O—C 1-4 alkyl, —SO 2 —C 1-4 alkyl, C 1-4 alkyl-SO 2 —R′, monocyclic cycloalkyl, —C 1-4 alkyl(monocyclic cycloalkyl), monocyclic heterocyclyl, —O-monocyclic heterocyclyl, or monocyclic heterocycloalkyl, each optionally substituted with one or two substituents selected from C 1-4 alkyl, —OH, —OC 1-4 alkyl, halo, or cyano or —NR p R q ;

wherein each R r is C 1-4 alkyl or —NR p R q ;

wherein R p and R q are each independently H or C 1-4 alkyl,

or R x and R y taken together with the nitrogen to which they are attached form a heterocyclyl, optionally substituted with C 1-4 alkyl;

or a pharmaceutically acceptable salt thereof.

15 . A compound selected from:

7-morpholino-2-(pyridin-4-yl)-N-(3-(p-tolyl)-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidin-5-amine;

7-morpholino-N-(5-phenyl-1H-pyrazol-3-yl)-2-(4-pyridyl)pyrazolo[1,5-a]pyrimidin-5-amine;

7-morpholino-N-[5-(o-tolyl)-1H-pyrazol-3-yl]-2-(4-pyridyl)pyrazolo[1,5-a]pyrimidin-5-amine;

7-morpholino-N-[3-(m-tolyl)-1H-pyrazol-5-yl]-2-(4-pyridyl)pyrazolo[1,5-a]pyrimidin-5-amine;

N-(5-methyl-1H-pyrazol-3-yl)-7-morpholino-2-(4-pyridyl)pyrazolo[1,5-a]pyrimidin-5-amine;

7-morpholino-2-(4-pyridyl)-N-[5-(4-pyridyl)-1H-pyrazol-3-yl]pyrazolo[1,5-a]pyrimidin-5-amine;

1-(7-morpholino-2-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-3-phenyl-1H-pyrazol-5-amine;

1-(7-morpholino-2-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-3-(o-tolyl)-1H-pyrazol-5-amine;

4-[5-(4-phenylpyrazol-1-yl)-2-(4-pyridyl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-[4-(m-tolyl)pyrazol-1-yl]-2-(4-pyridyl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[2-(4-pyridyl)-5-[4-(4-pyridyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-(4-methylpyrazol-1-yl)-2-(4-pyridyl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-(3-phenylpyrazol-1-yl)-2-(4-pyridyl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-[3-(m-tolyl)pyrazol-1-yl]-2-(4-pyridyl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[2-(4-pyridyl)-5-[3-(4-pyridyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-(3-methylpyrazol-1-yl)-2-(4-pyridyl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-(2-(pyridin-3-yl)-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-7-yl)morpholine;

4-(2-(pyridin-2-yl)-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-7-yl)morpholine;

N-ethyl-7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N-cyclopropyl-7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

(R)—N-(1-cyclopropylethyl)-7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

(S)—N-(1-cyclopropylethyl)-7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N-(2-methoxyethyl)-7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N,N-dimethyl-7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N-ethyl-N-methyl-7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N-cyclopropyl-N-methyl-7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N-(cyclopropylmethyl)-7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

azetidin-1-yl(7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-2-yl)methanone;

(7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-2-yl) (pyrrolidin-1-yl)methanone;

(7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-2-yl) (piperidin-1-yl)methanone;

morpholino (7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-2-yl)methanone;

(4-methylpiperazin-1-yl) (7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-2-yl)methanone;

N-methoxy-N-methyl-7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N-methoxy-7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N-(methylsulfonyl)-7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N-cyclopentyl-7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N-cyclopentyl-N-methyl-7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N-isopropyl-7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N-(1,3-dimethoxypropan-2-yl)-7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N-(2-(dimethylamino)ethyl)-7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N-(4-(dimethylamino)butyl)-7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

7-morpholino-N-(oxetan-3-yl)-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

7-morpholino-N-(oxetan-3-ylmethyl)-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N-((3-(hydroxymethyl) oxetan-3-yl)methyl)-7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

(7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-2-yl) (2-oxa-6-azaspiro[3.3]heptan-6-yl)methanone;

(7-morpholino-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-2-yl) (6-oxa-1-azaspiro[3.3]heptan-1-yl)methanone;

7-morpholino-N-(oxetan-3-yloxy)-5-(3-(m-tolyl)-1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N-[(3S)-1-methylpyrrolidin-3-yl]-7-morpholino-5-[3-(m-tolyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N-[(3R)-1-methylpyrrolidin-3-yl]-7-morpholino-5-[3-(m-tolyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine-2-carboxamide;

7-morpholino-5-[3-(m-tolyl)pyrazol-1-yl]-N-[(3S)-tetrahydrofuran-3-yl]pyrazolo[1,5-a]pyrimidine-2-carboxamide;

7-morpholino-5-[3-(m-tolyl)pyrazol-1-yl]-N-[(3R)-tetrahydrofuran-3-yl]pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N-[(3R)-1-methyl-3-piperidyl]-7-morpholino-5-[3-(m-tolyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N-[(3S)-1-methyl-3-piperidyl]-7-morpholino-5-[3-(m-tolyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N-(1-methyl-4-piperidyl)-7-morpholino-5-[3-(m-tolyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N-(1-methyl-4-piperidyl)-7-morpholino-5-[4-(m-tolyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidine-2-carboxamide;

7-morpholino-5-[4-(m-tolyl)pyrazol-1-yl]-N-tetrahydropyran-4-yl-pyrazolo[1,5-a]pyrimidine-2-carboxamide;

4-[5-[4-(m-tolyl)pyrazol-1-yl]-2-pyrimidin-4-yl-pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-[4-(m-tolyl)pyrazol-1-yl]-2-pyrimidin-5-yl-pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

3-[7-morpholino-5-[4-(m-tolyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidin-2-yl]pyridin-2-amine;

5-[7-morpholino-5-[4-(m-tolyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidin-2-yl]pyrimidin-2-amine;

4-[2-(1-methylpyrazol-3-yl)-5-[3-(m-tolyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-[3-(m-tolyl)pyrazol-1-yl]-2-(1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-(3-phenylpyrazol-1-yl)-2-pyrimidin-2-yl-pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-(3-phenylpyrazol-1-yl)-2-(3-pyridyl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[2-(5-methyl-1H-pyrazol-3-yl)-5-[3-(m-tolyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[2-(1-methylpyrazol-3-yl)-5-(3-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-(3-phenylpyrazol-1-yl)-2-(1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-(3-phenylpyrazol-1-yl)-2-pyrimidin-4-yl-pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-(3-phenylpyrazol-1-yl)-2-pyrimidin-5-yl-pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

3-[7-morpholino-5-(3-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-2-yl]pyridin-2-amine;

5-[7-morpholino-5-(3-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-2-yl]pyrimidin-2-amine;

4-[5-(3-phenylpyrazol-1-yl)-2-(2-pyridyl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

N-isopropyl-7-morpholino-5-(3-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N-[(1R)-1-cyclopropylethyl]-7-morpholino-5-(3-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N-[(1S)-1-cyclopropylethyl]-7-morpholino-5-(3-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

7-morpholino-N-(oxetan-3-ylmethyl)-5-(3-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

N-cyclopentyl-7-morpholino-5-(3-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

4-[5-(4-phenylpyrazol-1-yl)-2-(2-pyridyl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-(4-phenylpyrazol-1-yl)-2-(3-pyridyl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

N-isopropyl-7-morpholino-5-(4-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;

4-[2-(5-methyl-1H-pyrazol-3-yl)-5-(3-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-(3-phenylpyrazol-1-yl)-2-pyrazin-2-yl-pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

N,N-dimethyl-2-[3-methyl-5-[7-morpholino-5-[3-(m-tolyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidin-2-yl]pyrazol-1-yl]ethanamine;

4-[2-(2,5-dimethylpyrazol-3-yl)-5-[3-(m-tolyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[2-(2,5-dimethylpyrazol-3-yl)-5-(3-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[2-(1,5-dimethylpyrazol-3-yl)-5-(3-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[2-(1,5-dimethylpyrazol-3-yl)-5-[3-(m-tolyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-(3-phenylpyrazol-1-yl)-2-pyridazin-3-yl-pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

methyl N-[[7-morpholino-5-(3-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-2-yl]methyl]carbamate;

N-[[7-morpholino-5-(3-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-2-yl]methyl]propanamide;

N,N-dimethyl-2-[5-methyl-3-[7-morpholino-5-[3-(m-tolyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidin-2-yl]pyrazol-1-yl]ethanamine;

N,N-dimethyl-2-[5-methyl-3-[7-morpholino-5-[3-(2-pyridyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidin-2-yl]pyrazol-1-yl]ethanamine;

N,N-dimethyl-2-[5-methyl-3-[7-morpholino-5-[3-(4-pyridyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidin-2-yl]pyrazol-1-yl]ethanamine;

N,N-dimethyl-2-[5-methyl-3-[5-[3-(6-methyl-2-pyridyl)pyrazol-1-yl]-7-morpholino-pyrazolo[1,5-a]pyrimidin-2-yl]pyrazol-1-yl]ethanamine;

N,N-dimethyl-2-[5-methyl-3-[5-[3-(4-methyl-2-pyridyl)pyrazol-1-yl]-7-morpholino-pyrazolo[1,5-a]pyrimidin-2-yl]pyrazol-1-yl]ethanamine;

N,N-dimethyl-2-[5-methyl-3-[5-[3-(2-methyl-4-pyridyl)pyrazol-1-yl]-7-morpholino-pyrazolo[1,5-a]pyrimidin-2-yl]pyrazol-1-yl]ethanamine;

2-[3-[5-[3-(3-chlorophenyl)pyrazol-1-yl]-7-morpholino-pyrazolo[1,5-a]pyrimidin-2-yl]-5-methyl-pyrazol-1-yl]-N,N-dimethyl-ethanamine;

5-[7-morpholino-5-(3-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-2-yl]pyridin-2-amine;

N,N-dimethyl-2-[5-methyl-3-[7-morpholino-5-(3-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-2-yl]pyrazol-1-yl]ethanamine;

2-[3-[5-[3-(3-methoxyphenyl)pyrazol-1-yl]-7-morpholino-pyrazolo[1,5-a]pyrimidin-2-yl]-5-methyl-pyrazol-1-yl]-N,N-dimethyl-ethanamine;

4-[5-[3-(3-chlorophenyl)pyrazol-1-yl]-2-(1-methylpyrazol-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-[3-(5-methyl-3-pyridyl)pyrazol-1-yl]-2-(3-pyridyl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-[3-(2-methyl-4-pyridyl)pyrazol-1-yl]-2-(3-pyridyl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[7-morpholino-5-(3-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-2-yl]pyrimidin-2-amine;

4-[5-[3-(3-chlorophenyl)pyrazol-1-yl]-2-(3-pyridyl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-[3-(3-bromophenyl)pyrazol-1-yl]-2-(3-pyridyl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-[3-(3-methoxyphenyl)pyrazol-1-yl]-2-(3-pyridyl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-[3-(6-methyl-2-pyridyl)pyrazol-1-yl]-2-(3-pyridyl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

6-[7-morpholino-5-(3-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-2-yl]pyridin-2-amine;

4-[2-(3-methylisoxazol-5-yl)-5-[3-(m-tolyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-[3-(m-tolyl)pyrazol-1-yl]-2-thiazol-2-yl-pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[2-(1-methylpyrazol-4-yl)-5-[3-(m-tolyl)pyrazol-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-[3-(m-tolyl)pyrazol-1-yl]-2-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-(3-phenylpyrazol-1-yl)-2-thiazol-2-yl-pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[2-(1-methylpyrazol-4-yl)-5-(3-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[5-(3-phenylpyrazol-1-yl)-2-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

methyl 3-[1-[7-morpholino-2-(3-pyridyl)pyrazolo[1,5-a]pyrimidin-5-yl]pyrazol-3-yl]benzoate;

3-[1-[7-morpholino-2-(3-pyridyl)pyrazolo[1,5-a]pyrimidin-5-yl]pyrazol-3-yl]benzamide;

3-[1-[7-morpholino-2-(3-pyridyl)pyrazolo[1,5-a]pyrimidin-5-yl]pyrazol-3-yl]benzonitrile;

4-[5-[3-(m-tolyl)pyrazol-1-yl]-2-oxazol-2-yl-pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

4-[2-(3-methylisoxazol-5-yl)-5-(3-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

3-[1-[7-morpholino-2-(3-pyridyl)pyrazolo[1,5-a]pyrimidin-5-yl]pyrazol-3-yl]benzoic acid; and

4-[2-(1-methylpyrazol-3-yl)-5-[3-[3-(trideuteriomethyl)phenyl]pyrazol-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine;

and pharmaceutically acceptable salts thereof.

16 . The compound of claim 1 , wherein the compound of Formula (I) is selected from 4-[2-(5-methyl-1H-pyrazol-3-yl)-5-(3-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine and pharmaceutically acceptable salts thereof.

17 . The compound of claim 16 , wherein the compound of Formula (I) is 4-[2-(5-methyl-1H-pyrazol-3-yl)-5-(3-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine.

18 . A compound or a pharmaceutically acceptable salt of claim 1 , wherein one or more hydrogen atoms attached to carbon atoms of the compound are replaced by deuterium atoms.

19 . A pharmaceutical composition comprising a compound and/or a pharmaceutically acceptable salt of claim 1 and a pharmaceutically acceptable excipient.

20 . A method of inhibiting PIKfyve kinase in a subject in need thereof comprising administering to the subject an effective amount of a compound of claim 1 .

21 . A method of treating a neurological disease associated with PIKfyve activity in a subject in need thereof comprising administering to the subject an effective amount of a pharmaceutical composition of claim 19 .

22 . The method of claim 21 , wherein the neurological disease is amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), Charcot-Marie-Tooth (CMT; including type 4J (CMT4J)), and Yunis-Varon syndrome, autophagy, polymicrogyria (including polymicrogyria with seizures), temporo-occipital polymicrogyria, Pick's disease, Parkinson's disease, Parkinson's disease with Lewy bodies, dementia with Lewy bodies, Lewy body disease, fronto-temporal dementia, diseases of neuronal nuclear inclusions of polyglutamine and intranuclear inclusion bodies, disease of Marinesco and Hirano bodies, tauopathy, Alzheimer's disease, neurodegeneration, spongiform neurodegeneration, peripheral neuropathy, leukoencephalopathy, inclusion body disease, progressive supranuclear palsy, corticobasal syndrome, chronic traumatic encephalopathy, traumatic brain injury (TBI), cerebral ischemia, Guillain-Barré Syndrome, chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, a lysosomal storage disease, Fabry's disorder, Gaucher's disorder, Niemann Pick C disease, Tay-Sachs disease, and Mucolipidosis type IV, neuropathy, Huntington's disease, a psychiatric disorder, ADHD, schizophrenia, a mood disorder, major depressive disorder, depression, bipolar disorder I, or bipolar disorder II.

23 . The method of claim 22 , wherein the disease is ALS, FTD, Alzheimer's disease, Parkinson's disease, Huntington's disease, or CMT.

24 . The method of claim 23 , wherein the disease is ALS.

25 . The method of claim 23 , wherein the compound is selected from 4-[2-(5-methyl-1H-pyrazol-3-yl)-5-(3-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine and pharmaceutically acceptable salts thereof.

26 . The method of claim 25 , wherein the compound is 4-[2-(5-methyl-1H-pyrazol-3-yl)-5-(3-phenylpyrazol-1-yl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine.

27 . The method of claim 22 , wherein the disease is a tauopathy such as Alzheimer's disease, progressive supranuclear palsy, corticobasal syndrome, frontotemporal dementia, or chronic traumatic encephalopathy.

28 . The method of claim 22 , wherein the disease is a lysosomal storage disease such as Fabry's disorder, Gaucher's disorder, Niemann Pick C disease, Tay-Sachs disease, or Mucolipidosis type IV.

29 . The method of claim 22 , wherein the disease is a psychiatric disorder such as ADHD, schizophrenia, or mood disorders such as major depressive disorder, depression, bipolar disorder I, or bipolar disorder II.

Continuity (3)
Provisional Application 63074388 · Sep 3, 2020
Provisional Application 62960412 · Jan 13, 2020
Related Publication 20230133203A1 · May 4, 2023
References Cited (280)
US 6194410B1 · Bös et al. · 2001 [cited by applicant]
US 6384032B1 · Ono et al. · 2002 [cited by applicant]
US 6423751B1 · Liao · 2002 [cited by applicant]
US 6680315B2 · Ono et al. · 2004 [cited by applicant]
US 7045517B2 · Ono et al. · 2006 [cited by applicant]
US 7473694B2 · Unoki et al. · 2009 [cited by applicant]
US 7531536B2 · Bebbington et al. · 2009 [cited by applicant]
US 7550470B2 · Fraley · 2009 [cited by applicant]
US 7557110B2 · Kataoka et al. · 2009 [cited by applicant]
US 7645762B2 · Paruch et al. · 2010 [cited by applicant]
US 7700583B2 · Gundertofte et al. · 2010 [cited by applicant]
US 7951820B2 · Bebbington et al. · 2011 [cited by applicant]
US 8314098B2 · Yamamoto et al. · 2012 [cited by applicant]
US 8486938B2 · Babaoglu et al. · 2013 [cited by applicant]
US 8551981B2 · Calderwood et al. · 2013 [cited by applicant]
US 8697698B2 · Bebbington et al. · 2014 [cited by applicant]
US 8969376B2 · Kawanishi et al. · 2015 [cited by applicant]
US 8980878B2 · Siegel et al. · 2015 [cited by applicant]
US 9096605B2 · Lin et al. · 2015 [cited by applicant]
US 9656996B2 · Xu et al. · 2017 [cited by applicant]
US 9981976B2 · Tahari et al. · 2018 [cited by applicant]
US 10138247B2 · Dymek et al. · 2018 [cited by applicant]
US 10702534B2 · Landrette et al. · 2020 [cited by applicant]
US 10729694B2 · Lichenstein et al. · 2020 [cited by applicant]
US 10751345B2 · Lichenstein et al. · 2020 [cited by applicant]
US 10758545B2 · Ichida et al. · 2020 [cited by applicant]
US 10765682B2 · Beeharry et al. · 2020 [cited by applicant]
US 11266654B2 · Lichenstein et al. · 2022 [cited by applicant]
US 11352354B2 · Deng et al. · 2022 [cited by applicant]
US 11439649B2 · Lichenstein et al. · 2022 [cited by applicant]
US 11471460B2 · DePamphilis et al. · 2022 [cited by applicant]
US 20020082259A1 · Ono et al. · 2002 [cited by applicant]
US 20040053926A1 · Ono et al. · 2004 [cited by applicant]
US 20050038023A1 · Bebbington et al. · 2005 [cited by applicant]
US 20060069090A1 · Ono et al. · 2006 [cited by applicant]
US 20060258658A1 · Bebbington et al. · 2006 [cited by applicant]
US 20070027156A1 · Nakai et al. · 2007 [cited by applicant]
US 20090176778A1 · Schmitz et al. · 2009 [cited by applicant]
US 20100204265A1 · Baskaran et al. · 2010 [cited by applicant]
US 20110098267A1 · Babu et al. · 2011 [cited by applicant]
US 20110294781A1 · Yamamoto · 2011 [cited by examiner]
US 20120083498A1 · Kashanchi · 2012 [cited by applicant]
US 20130096128A1 · Bebbington et al. · 2013 [cited by applicant]
US 20180036420A1 · Xu et al. · 2018 [cited by applicant]
US 20180050041A1 · Conrad et al. · 2018 [cited by applicant]
US 20180141969A1 · Hwang et al. · 2018 [cited by applicant]
US 20180199623A1 · Bebee et al. · 2018 [cited by applicant]
US 20180265464A1 · Edinger et al. · 2018 [cited by applicant]
US 20180280403A1 · Landrette et al. · 2018 [cited by applicant]
US 20190070166A1 · Postrel · 2019 [cited by applicant]
US 20200079780A1 · Romanov et al. · 2020 [cited by applicant]
US 20200165246A1 · Deng et al. · 2020 [cited by applicant]
US 20200199136A1 · Smrcina et al. · 2020 [cited by applicant]
US 20200306255A1 · Conrad et al. · 2020 [cited by applicant]
US 20200369649A1 · DePamphilis et al. · 2020 [cited by applicant]
US 20210002296A1 · Mainolfi et al. · 2021 [cited by applicant]
US 20210033597A1 · Ichida et al. · 2021 [cited by applicant]
US 20210047405A1 · Nobles et al. · 2021 [cited by applicant]
US 20210062160A1 · Rohwer et al. · 2021 [cited by applicant]
US 20210077500A1 · Landrette et al. · 2021 [cited by applicant]
US 20210139486A1 · Mohan et al. · 2021 [cited by applicant]
US 20210244743A1 · Landrette et al. · 2021 [cited by applicant]
US 20210338683A1 · Ichida et al. · 2021 [cited by applicant]
US 20220144838A1 · Fong et al. · 2022 [cited by applicant]
US 20220160741A1 · Newman et al. · 2022 [cited by applicant]
US 20220168402A1 · Cantley et al. · 2022 [cited by applicant]
US 20220267332A1 · Cai et al. · 2022 [cited by applicant]
US 20220332723A1 · Kotian et al. · 2022 [cited by applicant]
US 20220380769A1 · Equels et al. · 2022 [cited by applicant]
US 20220409617A1 · Edinger · 2022 [cited by applicant]
US 20220411804A1 · Chang et al. · 2022 [cited by applicant]
US 20230038929A1 · Rosen · 2023 [cited by applicant]
US 20230069069A1 · Lichenstein et al. · 2023 [cited by applicant]
US 20230133203A1 · Rosen · 2023 [cited by applicant]
CN 103242341A · 2013 [cited by applicant]
CN 105820175A · 2016 [cited by applicant]
CN 105963300A · 2016 [cited by applicant]
CN 106957303A · 2017 [cited by applicant]
CN 107163061A · 2017 [cited by applicant]
CN 108586486A · 2018 [cited by applicant]
CN 112142744A · 2020 [cited by applicant]
EP 1277738A1 · 2003 [cited by applicant]
EP 2520659A1 · 2012 [cited by applicant]
EP 3096757A1 · 2016 [cited by applicant]
EP 3215159A1 · 2017 [cited by applicant]
EP 3253389A1 · 2017 [cited by applicant]
EP 3215157B1 · 2019 [cited by applicant]
EP 3215158B1 · 2019 [cited by applicant]
EP 3581184B1 · 2021 [cited by applicant]
EP 3325014B1 · 2021 [cited by applicant]
JP 2004277337A · 2004 [cited by applicant]
JP 2006160628A · 2006 [cited by applicant]
JP 2013060438A · 2013 [cited by applicant]
JP 5531066B2 · 2014 [cited by applicant]
JP 6220059B2 · 2017 [cited by applicant]
WO 2000078757A1 · 2000 [cited by applicant]
WO 2002087513A2 · 2002 [cited by applicant]
WO 2002088079A2 · 2002 [cited by applicant]
WO 2002088080A2 · 2002 [cited by applicant]
WO 2002102313A2 · 2002 [cited by applicant]
WO 2002102314A2 · 2002 [cited by applicant]
WO 2002102315A2 · 2002 [cited by applicant]
WO 2004017950A2 · 2004 [cited by applicant]
WO 2005000404A2 · 2005 [cited by applicant]
WO 2005009539A2 · 2005 [cited by applicant]
WO 2005023806A2 · 2005 [cited by applicant]
WO 2005046603A2 · 2005 [cited by applicant]
WO 2005046698A1 · 2005 [cited by applicant]
WO 2006007532A2 · 2006 [cited by applicant]
WO 2006010567A1 · 2006 [cited by applicant]
WO 2006034402A2 · 2006 [cited by applicant]
WO 2006053109A1 · 2006 [cited by applicant]
WO 2006055747A2 · 2006 [cited by applicant]
WO 2006081389A1 · 2006 [cited by applicant]
WO 2006081391A2 · 2006 [cited by applicant]
WO 2006083477A2 · 2006 [cited by applicant]
WO 2006128129A2 · 2006 [cited by applicant]
WO 2006128172A2 · 2006 [cited by applicant]
WO 2007023110A2 · 2007 [cited by applicant]
WO 2007023382A2 · 2007 [cited by applicant]
WO 2007050980A2 · 2007 [cited by applicant]
WO 2007060404A1 · 2007 [cited by applicant]
WO 2007071688A1 · 2007 [cited by applicant]
WO 2007087427A2 · 2007 [cited by applicant]
WO 2007087429A2 · 2007 [cited by applicant]
WO 2007087441A2 · 2007 [cited by applicant]
WO 2007087442A2 · 2007 [cited by applicant]
WO 2007087443A2 · 2007 [cited by applicant]
WO 2007089904A2 · 2007 [cited by applicant]
WO 2007090852A1 · 2007 [cited by applicant]
WO 2007109362A2 · 2007 [cited by applicant]
WO 2007112093A2 · 2007 [cited by applicant]
WO 2007114323A1 · 2007 [cited by applicant]
WO 2007127183A1 · 2007 [cited by applicant]
WO 2008008359A2 · 2008 [cited by applicant]
WO 2008024302A2 · 2008 [cited by applicant]
WO 2008024303A2 · 2008 [cited by applicant]
WO 2008024304A2 · 2008 [cited by applicant]
WO 2008039520A2 · 2008 [cited by applicant]
WO 2008057246A2 · 2008 [cited by applicant]
WO 2008063504A2 · 2008 [cited by applicant]
WO 2008103310A1 · 2008 [cited by applicant]
WO 2008130570A1 · 2008 [cited by applicant]
WO 2008132502A1 · 2008 [cited by applicant]
WO 2008136976A2 · 2008 [cited by applicant]
WO 2008147626A2 · 2008 [cited by applicant]
WO 2009007753A2 · 2009 [cited by applicant]
WO 2009015254A1 · 2009 [cited by applicant]
WO 2009016410A2 · 2009 [cited by applicant]
WO 2009017818A1 · 2009 [cited by applicant]
WO 2009017819A1 · 2009 [cited by applicant]
WO 2009017831A1 · 2009 [cited by applicant]
WO 2009020631A2 · 2009 [cited by applicant]
WO 2009038775A1 · 2009 [cited by applicant]
WO 2009070567A1 · 2009 [cited by applicant]
WO 2009089305A1 · 2009 [cited by applicant]
WO 2009100406A2 · 2009 [cited by applicant]
WO 2009105257A1 · 2009 [cited by applicant]
WO 2010039236A1 · 2010 [cited by applicant]
WO 2010039237A1 · 2010 [cited by applicant]
WO 2010039238A1 · 2010 [cited by applicant]
WO 2010052569A2 · 2010 [cited by applicant]
WO 2010086040A1 · 2010 [cited by applicant]
WO 2010091409A1 · 2010 [cited by applicant]
WO 2010118207A1 · 2010 [cited by applicant]
WO 2011031979A1 · 2011 [cited by applicant]
WO 2011081171A1 · 2011 [cited by applicant]
WO 2011105628A1 · 2011 [cited by applicant]
WO 2011146727A1 · 2011 [cited by applicant]
WO 2012027240A1 · 2012 [cited by applicant]
WO 2012037116A2 · 2012 [cited by applicant]
WO 2012047569A1 · 2012 [cited by applicant]
WO 2012064808A1 · 2012 [cited by applicant]
WO 2012103081A1 · 2012 [cited by applicant]
WO 2012112245A1 · 2012 [cited by applicant]
WO 2012147890A1 · 2012 [cited by applicant]
WO 2012170827A2 · 2012 [cited by applicant]
WO 2013028263A1 · 2013 [cited by applicant]
WO 2013063385A1 · 2013 [cited by applicant]
WO 2015112888A1 · 2015 [cited by applicant]
WO 2015118434A1 · 2015 [cited by applicant]
WO 2015173683A1 · 2015 [cited by applicant]
WO 2016033445A1 · 2016 [cited by applicant]
WO 2016073871A1 · 2016 [cited by applicant]
WO 2016073877A1 · 2016 [cited by applicant]
WO 2016073884A1 · 2016 [cited by applicant]
WO 2016112072A1 · 2016 [cited by applicant]
WO 2016118709A1 · 2016 [cited by applicant]
WO 2016126707A1 · 2016 [cited by applicant]
WO 2016148145A1 · 2016 [cited by applicant]
WO 2016157091A1 · 2016 [cited by applicant]
WO 2016160102A1 · 2016 [cited by applicant]
WO 2016161145A1 · 2016 [cited by applicant]
WO 2016210372A2 · 2016 [cited by applicant]
WO 2017002120A1 · 2017 [cited by applicant]
WO 2017015262A1 · 2017 [cited by applicant]
WO 2017019537A1 · 2017 [cited by applicant]
WO 2017029521A1 · 2017 [cited by applicant]
WO 2017040971A1 · 2017 [cited by applicant]
WO 2017055305A1 · 2017 [cited by applicant]
WO 2017069270A1 · 2017 [cited by applicant]
WO 2017090058A1 · 2017 [cited by applicant]
WO 2017127661A1 · 2017 [cited by applicant]
WO 2018039022A1 · 2018 [cited by applicant]
WO 2018055152A1 · 2018 [cited by applicant]
WO 2018071548A1 · 2018 [cited by applicant]
WO 2018092047A1 · 2018 [cited by applicant]
WO 2018138106A1 · 2018 [cited by applicant]
WO 2018175906A1 · 2018 [cited by applicant]
WO 2018226150A1 · 2018 [cited by applicant]
WO 2019024908A1 · 2019 [cited by applicant]
WO 2019027765A1 · 2019 [cited by applicant]
WO 2019046316A1 · 2019 [cited by applicant]
WO 2019108665A1 · 2019 [cited by applicant]
WO 2019113523A1 · 2019 [cited by applicant]
WO 2019164861A1 · 2019 [cited by applicant]
WO 2019244050A1 · 2019 [cited by applicant]
WO 2020009971A1 · 2020 [cited by applicant]
WO 2020025960A1 · 2020 [cited by applicant]
WO 2020035049A1 · 2020 [cited by applicant]
WO 2021097286A1 · 2021 [cited by applicant]
WO 2021113633A1 · 2021 [cited by applicant]
WO 2021146192A1 · 2021 [cited by applicant]
WO 2021151100A1 · 2021 [cited by applicant]
WO 2021155067A1 · 2021 [cited by applicant]
WO 2021163727A1 · 2021 [cited by applicant]
WO 2021183439A1 · 2021 [cited by applicant]
WO 2021247841A1 · 2021 [cited by applicant]
WO 2021247859A1 · 2021 [cited by applicant]
WO 2021247862A1 · 2021 [cited by applicant]
WO 2021252895A2 · 2021 [cited by applicant]
WO 2022012484A1 · 2022 [cited by applicant]
WO 2022086993A1 · 2022 [cited by applicant]
WO 2022094058A1 · 2022 [cited by applicant]
WO 2022094615A1 · 2022 [cited by applicant]
WO 2022235975A2 · 2022 [cited by applicant]
WO 2022261499A1 · 2022 [cited by applicant]
Cai, Xinming, et al. “PIKfyve, a Class III PI Kinase, Is the Target of the Small Molecular IL-12/IL-23 Inhibitor Apilimod and a Player in Toll-like Receptor Signaling.” Chemistry & Biology, vol. 20, No. 7, Jul. 2013, pp… [cited by examiner]
International Search Report issued in International Application No. PCT/US2021/013077, dated May 19, 2021, 9 pages. [cited by applicant]
U.S. Appl. No. 17/910,082, filed Sep. 8, 2022, Mark D. Rosen. [cited by applicant]
Bakkar et al., “The M1311V variant of ATP7A is associated with impaired trafficking and copper homeostasis in models of motor neuron disease”, Neurobiology of Disease, vol. 149, 105228, pp. 1-29 (2021). [cited by applicant]
Baranov et al., “The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19”, Cells, vol. 10, p. 30 (2021). [cited by applicant]
Blythe, Alexander David, “Investigating Tdp-43-Dependent Neuronal Trafficking Disruption in a [cited by applicant]
Bowles et al., “ELAVL4, splicing, and glutamatergic dysfunction precede neuron loss in MAPT mutation cerebral organoids”, Cell, vol. 184(17), pp. 4547-4563 (2021). [cited by applicant]
Bowles et al., “Glutamatergic dysfunction precedes neuron loss in cerebral organoids with MAPT mutation”, bioRxiv, 429623 (2021). [cited by applicant]
Burke et al., “Beyond PI3Ks: targeting phosphoinositide kinases in disease”, Nature Reviews Drug Discovery (2022). [cited by applicant]
Cinato et al., “Apilimod alters TGFβ signaling pathway and prevents cardiac fibrotic remodeling”, Theranostics, vol. 11(13), pp. 6491-6506 (2021). [cited by applicant]
Guan et al., “Discovery of novel Jak2-Stat pathway inhibitors with extended residence time on target”, Bioorganic & Medicinal Chem. Letters, vol. 23(10), pp. 3105-3110, (2013). [cited by applicant]
Guo et al., “The multifaceted role of kinases in amyotrophic lateral sclerosis: genetic, pathological and therapeutic implications”, Brain, vol. 143(6), pp. 1651-1673 (2020). [cited by applicant]
Hayakawa et al., “Synthesis and biological evaludation of pyrido [3′,2′:4,6] furo [3,2-d] pyrimidine derivatives as novel PI3 kinase p110@a inhibitors”, Biorganic & medicinal Chemistry Letters, Elsevier, Amsterdam, NL, … [cited by applicant]
Hoemann et al., “Synthesis and optimization of furano [3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors”, Biorganic & Medicinal Chemistry Letters, vol. 26, No. 22, Oct. 11, 2016, pp. 5562-5567. [cited by applicant]
Hung et al., “PIKFYVE inhibition mitigates disease in models of diverse forms of ALS”, Cell. Feb. 16, 2023;186(4):786-802.e28. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2022/014954, dated Jun. 15, 2022, 11 pages. [cited by applicant]
International Search Report and Written Opinion, International Application No. PCT/US2021/021369, Apr. 28, 2021, 12 pages. [cited by applicant]
International Search Report issued in International Application No. PCT/US2020/063298, dated Feb. 3, 2021, 10 pages. [cited by applicant]
Jasuja et al., “Pharmacophore and docking-based virtual screening approach for the design of new dual inhibitors of Janus kinase 1 and Janus kinase 2”, SAR and QSAR in Environ. Research, vol. 25(8), p. 617-636 (2014). [cited by applicant]
Kelarev et al., “Synthesis of amine derivatives of 1,3,5-triazine containing 1,3,4-thiadiazole fragments”, Izvestiya Vysshikh Uchebnykh Zavedenii, Khimiya i Khimicheskaya Tekhnologiya, vol. 40(2), pp. 27-32, (1997). Eng… [cited by applicant]
Kreutzberger et al., “Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease”, J Virol., vol. 95(21), p. e0097521 (2021). [cited by applicant]
Kueth, C., “PIKFYVE Modulation Mitigates TDP-43-Dependent Disease Phenotypes in a [cited by applicant]
Li, PeiQi, “Elucidation of VPS13 and PIKfyve Proteins Functioning in the Regulation of Eukaryotic Lipid Homeostasis”, Yale Dissertation (2021). [cited by applicant]
Ou et al. “Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV”, Nature Communications, vol. 11, No. 1, pp. 1-12 (2020). [cited by applicant]
Rangnekar et al., “Synthesis and dyeing characteristics of 3,6-bisarylazopyrazolo-[1,5-alpha]pyrimidines”, Indian Journal of Fibre & Textile Research, vol. 15, pp. 23-25 (1990). [cited by applicant]
Rivero-Rios et al., “Roles of PIKfyve in multiple cellular pathways”, Curr Opin Cell Biol. Jun. 2022;76:102086. [cited by applicant]
See et al., “PIKfyve inhibition blocks endolysosomal escape of alpha-synuclein fibrils and spread of a-synuclein aggregation”, bioRxiv, 427704 (2021). [cited by applicant]
Sharma et al., “A family of PIKFYVE inhibitors with therapeutic potential against autophagy-dependent cancer cells disrupt multiple events in lysosome homeostasis”, Autophagy, vol. 15.10, pp. 1694-1718 (2019). [cited by applicant]
Shi et al., “Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons”, Nat Med, vol. 24(3), pp. 313-325 (2018). [cited by applicant]
Staats et al., “Small molecule inhibition of PIKFYVE kinase rescues gain- and loss-of-function C9ORF72 ALS/FTD disease processes in vivo”, https://www.biorxiv.org/content/10.1101/685800v1.abstract (2019). [cited by applicant]
Sun et al., “Rational Design and Synthesis of D-galactosyl Lysophospholipids as Selective Substrates and non-ATP-competitive Inhibitors of Phosphatidylinositol Phosphate Kinases”, Chemistry. Jan. 9, 2023;29(2):e20220208… [cited by applicant]
Yu et al., “Design, Synthesis and biological evaluation of novel thienopyrimidine derivatives as PI3Ka inhibitors”, Molecules, vol. 24(19), p. 3422 (2019). [cited by applicant]
Zhan et al., “Design, Synthesis and biological evaluation of Dimorpholine Substituted Thienopyrimidines as Potential Class 1 PI3K/mTOR Dual Inhibitors”, Molecules, vol. 60(9), pp. 4023-4035 (2017). [cited by applicant]
Zhang et al., “Virus-Free and Live-Cell Visualizing SARS-CoV-2 Cell Entry for Studies of Neutraliztin Antibodies and Compound Inhibitors”, Small Methods, vol. 5, No. 2, p. 2001031 (2020). [cited by applicant]
Jeffries et al., “A selective PIKfyve inhibitor blocks PtdIns(3,5)P2 production and disrupts endomembrane transport and retroviral budding” EMBO Reports, Nature Publishing Group, vol. 9, No. 2, pp. 164-170 (2008). [cited by applicant]
Baraldi et al., “Synthesis of a new series of pyrazolo[1,5-a]pyrimidines structurally related to zaleplon,” Journal of Heterocyclic Chemistry 44(2), pp. 355-361 (2007). [cited by applicant]
Kosugi et al., “Correction to Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAP-K2) as an Antiinflammatory Target: Discovery and in Vivo Activity of Selective Pyrazolo[1,5-a]pyrimidine Inhibitors Using… [cited by applicant]
Kosugi et al., “Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAP-K2) as an Antiinflammatory Target: Discovery and in Vivo Activity of Selective Pyrazolo[1,5-a]pyrimidine Inhibitors Using a Focused Lib… [cited by applicant]
Liu et al., “Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent,” ACS Medicinal Chemistry Letters, vol. 7, Issue: 7, pp. 671-675 (2016). [cited by applicant]
Paruch et al, “Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases,” ACS Medicinal Chemistry Letters, vol. 1, Issue: 5, pp. 204-208 (2010). [cited by applicant]
Plisson et al., “Phosphodiesterase 10A PET radioligand development program: from pig to human,” Journal of Nuclear Medicine, vol. 55, Issue: 4, pp. 595-601 (2014). [cited by applicant]
Saito et al., “Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF1) receptor antagonists,” Bioorganic & Medicinal Chemistry, vol. 19, Issue: 2… [cited by applicant]
Wells et al., “SGC-CK2-1: the first selective chemical probe for the pleiotropic kinase CK2,” Structural Genomics Consortium (SGC), UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill (UNC-CH), … [cited by applicant]